Intraoperative Floppy Iris Syndrome
An assessment of the surgical performance of DisCoVisc compared to Healon5 during cataract surgery with intraocular lens implantation where miotic/small pupils or intraoperative Floppy Iris Syndrome exists.
Floppy Iris Syndrome
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
- Corneal Endothelial Cell Loss [ Time Frame: 1 month ] [ Designated as safety issue: Yes ]Endothelial cell loss/gain is measured by comparing the preoperative assessment of endothelial cell density against postoperative measurements. Measurements are made with a specular microscope, which takes a picture and numbers endothelial cells. This endpoint compares the assessment done at 1 month against the assessment done at baseline. A negative number indicates a loss of endothelial cells, a positive number indicates a gain in endothelial cells.
- Intraocular Pressure (IOP) [ Time Frame: 1 Day Postoperative ] [ Designated as safety issue: Yes ]Intraocular Pressure (IOP) is assessed with a slit lamp by means of Applanation (Goldmann) tonometry. This type of tonometry uses a small probe to gently flatten part of your cornea to measure eye pressure. The pressure in your eye is measured by how much force is needed to flatten your cornea, and measured in millimeters of mercury (mmHg). Normally, IOP should be less than 21 mmHg.
- Aqueous Signs - Cells [ Time Frame: 1 Day Postoperative ] [ Designated as safety issue: Yes ]Aqueous Cells are the foggy appearance given by protein that has leaked from inflamed blood vessels. This is evaluated by the surgeon one day post surgery and rated on the following scale: None, 0: 1-5 cells, 1: 6-15 cells, 2: 16-30 cells, 3: >30 cells
- Aqueous Signs - Flare [ Time Frame: 1 Day Postoperative ] [ Designated as safety issue: Yes ]
Aqueous Flare refers to individual inflammatory cells. Aqueous flare is evaluated by the surgeon one day after surgery and rated on the following scale:
0:No-Visible flare when compared with the normal eye.
- Mild-Flare visible against dark papillary background but not visible against iris background.
- Moderate-flare is visible with the slit-lamp beam aimed onto the iris surface as well as the dark papillary background.
- Severe-Very dense flare. May also present as a hazy appearance of anterior segment structures when viewed with low power magnification of the slit-lamp.
- Aqueous Signs - Edema [ Time Frame: 1 Day Postoperative ] [ Designated as safety issue: Yes ]
Aqueous signs refers cornea edema evaluated by the surgeon one day after surgery. Corneal edema is evaluated by the following scale:
0 = none
- = mild - slight localized or generalized edema
- = moderate - significant localized or generalized edema
- = severe - advanced localized or generalized edema
- Surgeon Survey [ Time Frame: Time of Surgery ] [ Designated as safety issue: No ]
Survey completed by the surgeon to evaluate use of the product during surgery. Responses are rated on the following scale and the means of the responses are reported:
Overall surgical difficulty: 1 - very easy; 2 - easy; 3 - neither easy nor difficult; 4 - difficult; 5 - very difficult
Satisfaction with performance: 1 - strongly disagree; 2 - disagree; 3 - undecided/neutral; 4 - agree; 5 - strongly agree
Ability to expand pupil: 1 - not effective; 2 - moderately effective; 3 - very effective
|Study Start Date:||June 2007|
|Study Completion Date:||April 2008|
|Primary Completion Date:||April 2008 (Final data collection date for primary outcome measure)|
Active Comparator: DisCoVisc
Alcon's DisCoVisc Ophthalmic Viscosurgical Device (OVD) used at time of cataract surgery
Use of Alcon's DisCoVisc Ophthalmic Viscosurgical Device(4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery with intraocular lens implantation.
Active Comparator: Healon5
Abbott Medical Optic's (AMO) Healon5 Ophthalmic Viscosurgical Device (OVD) used at time of cataract surgery
Use of Abbott Medical Optics (AMO) Healon5 Ophthalmic Viscosurgical Device (2.3% Sodium Hyaluronate) during cataract surgery with intraocular lens implantation.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00711347
|United States, Texas|
|Contact Alcon Call Center for Study Locations|
|Fort Worth, Texas, United States, 76134|